Next generation immunotherapeutics--honing the magic bullet.
Curr Opin Biotechnol
; 20(4): 405-11, 2009 Aug.
Article
en En
| MEDLINE
| ID: mdl-19709876
ABSTRACT
Most therapeutic antibodies in the clinic today are based on fully humanised immunoglobulins. They have proven to be outstandingly effective, especially for the treatment of cancer, autoimmune and inflammatory diseases where the target is a single, well-defined and accessible molecule. Many diseases however are complex, involving multiple mediators or signalling pathways that could be targeted simultaneously to maximise clinical benefit. There is also a wealth of validated intracellular and CNS-based targets which are currently inaccessible to monoclonal antibody therapy. A spectrum of next generation immunotherapeutics is in development to address these issues and a number of them have also entered clinical trials.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fragmentos de Inmunoglobulinas
/
Inmunoterapia
Límite:
Humans
Idioma:
En
Revista:
Curr Opin Biotechnol
Asunto de la revista:
BIOTECNOLOGIA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Reino Unido